InSphero AG has entered into an agreement with Pfizer to develop a novel predictive toxicology assay using InSphero’s 3D InSight Human Liver Microtissues. This mechanistic in vitro assay aimd to leverage the enhanced sensitivity and longevity of InSphero 3D liver models to help detect and predict mechanisms of drug toxicity. The agreement involves InSphero scientists in the U.S. Brunswick, ME and Schlieren, Switzerland facilities, with input from Pfizer scientists. InSphero chief exe...